Article

Pegaptanib approval process begins overseas

San Carlos, CA-The international approval process of pegaptanib sodium injection (Macugen) as a potential treatment for neovascular age-related macular degeneration is under way, as the companies begin filings in Europe, Canada, and Japan.

San Carlos, CA-The international approval process of pegaptanib sodium injection (Macugen) as a potential treatment for neovascular age-related macular degeneration is under way, as the companies begin filings in Europe, Canada, and Japan.

Nektar Therapeutics, Pfizer Ophthalmics, and Eyetech Pharmaceuticals Inc. said the European Medicines Agency has accepted the filing of their marketing authorization application. The companies also have filed a new drug application in Canada, where it has been designated for priority review. Meanwhile, clinical trials have begun in Japan.

The drug is under priority review by the FDA. It is being developed by Eyetech Pharmaceuticals with PEGylation technology from Nektar Therapeutics. Pfizer Ophthalmics holds marketing rights to the drug outside the United States, and will pay royalties to Eyetech Pharmaceuticals for those sales. Pfizer Ophthalmics and Eyetech Pharmaceuticals will share marketing responsibilities within the United States.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.